Recs

0

Jones, Maxwell Negotiate

In a news release that was oddly reminiscent of the big-city dating scene, Jones Apparel Group (NYSE: JNY  ) yesterday announced that what has amounted to nearly four months of acrimony has finally evolved into "negotiations" now that it appears Jones has offered Maxwell Shoe (Nasdaq: MAXS  ) enough money.

To sum up: Jones offered $20 per share in cash in an unsolicited bid in February; Maxwell balked. Jones tried a hostile takeover a month later; Maxwell told its investors to stay away, and they did. Jones bumped its offer to $22.50 in late May; a while later, Maxwell shot back with a statement calling the second offer, like the first, "financially inadequate."

And yesterday, Jones unexpectedly said it's in "talks" with Maxwell's management about a $23.25-per-share offer, subject to the companies hammering out a merger agreement, Maxwell's board approving it, and all of this happening before Friday. (Jones' tender offer is set to expire Friday, and Jones is demanding that it either have a merger agreement in its hot little hand or Maxwell investors tender enough shares to it that it can reshape Maxwell's board in its image by that date.)

This is a perfect illustration of the sort of chicken game (makes you think of the tractor duel in Footloose, doesn't it?) that hostile and/or unsolicited buyout offers often represent: They're invariably exciting to watch, but can be nerve-racking if you've got something invested. These kinds of offers have been in the news a lot lately, from Oracle's (Nasdaq: ORCL  ) attempts to buyPeopleSoft (Nasdaq: PSFT  ) to Wine Group's efforts to keep Golden State Vintners' (Nasdaq: VINT  ) management from taking the company private on the cheap.

Sometimes the companies reach a deal; sometimes they come to an impasse; and sometimes a white knight comes in and plucks the takeover target out of the would-be acquirer's grasp, as Aventis (NYSE: AVE  ) hoped Novartis (NYSE: NVS  ) would do before it gave in to Sanofi-Synthelabo (NYSE: SNY  ) . (In that case, the white knight rode off into the sunset without the princess.)

Given the publicity that such discussions sometimes get, it can be tempting for investors to attempt to "play" hostile deals for quick gains, but beware: Some research suggests that deals of this sort -- and the negotiations that accompany them -- reflect conscious strategic maneuvers (pdf file) most individual investors aren't privy to. That adds an extra layer of challenge to any analysis of a potential deal and both its short- and long-term impact.

Fool contributor Dave Marino-Nachison misses Grandpa Harold. He owns shares in Oracle.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 508525, ~/Articles/ArticleHandler.aspx, 2/14/2012 11:47:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 12,854.93 -19.11 -0.15%
S&P 500 1,347.95 -3.82 -0.28%
NASD 2,918.63 -12.76 -0.44%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/14/2012 11:19 AM
ORCL $28.36 Down -0.08 -0.26%
Oracle Corp. CAPS Rating: ****
SNY $37.20 Down -0.37 -0.98%
Sanofi (ADR) CAPS Rating: *****
JNY $9.76 Down -0.11 -1.11%
The Jones Group In… CAPS Rating: ***
NVS $56.36 Down -0.18 -0.32%
Novartis CAPS Rating: *****

Advertisement